Scopolamine Patch shortage
Not a nationwide shortage — Padagis US has told the FDA it is discontinuing its scopolamine patches. The FDA lists this under “To be discontinued” as of Oct 6, 2026: a company stopping its own product. 7 other companies sell the same medicine and have not reported a problem, so your pharmacy may be able to order another company’s version.
Padagis is permanently stopping its scopolamine transdermal patch, which may remove one source of this medicine. The 1 mg patch (including Transderm Scop) is still listed as available from other manufacturers not reporting a shortage.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this medicine? See the ‘What to do’ note from Dr. Brian Staiger, PharmD →Is scopolamine still in shortage? — status as of Oct 6, 2026
Still listed as “To be discontinued” as of Oct 6, 2026. Padagis US is stopping its own version only; 7 other companies still sell the same medicine and have not reported a problem. Your pharmacy may need to order another company’s version.
The charts count only the companies that reported this shortage to the FDA; companies that haven’t reported a problem are in the green card, and the Supply-Risk rating counts them too.
Shortage timeline
-
Nov 3, 2025Currently in shortage1 of 1 product affected.
-
Nov 3, 2025First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
Which scopolamine products are affected — by company
Company: Padagis US LLC 📞 866-634-9120 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Scopolamine Patch, 1 mg | 1 mg | — | Discontinuation of the manufacture of the drug | — |
These rows are company reports to the FDA for Scopolamine Patch — they do not cover every company that lists this medicine. A company appears here only if it told the FDA it has a supply problem, so other companies may still have stock. That’s the basis for the Where else can I get scopolamine? options further down this page.
Why is Padagis US discontinuing scopolamine?
Padagis US LLC has let the FDA know that they are permanently stopping the manufacture of their scopolamine 1 mg transdermal patch (the patch you wear behind your ear). This specific product — the 1 mg patch with NDC 45802-580-46 — will no longer be made by this company going forward.
It's worth knowing that Padagis did not share a specific public reason for why they made this decision — just that they are discontinuing production of this product. This report reflects only what Padagis has filed with the FDA, so it applies to their version of the patch specifically, not necessarily every version of scopolamine patches available on the market.
Based on the company-reported reason(s) and notes on file with the FDA for Scopolamine Patch, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as companies report changes.
What should I do if I take scopolamine?
The scopolamine transdermal patch (the skin patch many people use for motion sickness and nausea) is currently on the FDA shortage list. This note reflects one manufacturer's report, not the whole market.
The report covers the 1 mg patch, which is the only strength involved. The company that filed this report, Padagis US LLC, has marked this product to be discontinued — meaning they are stopping manufacture of it. Because this is a discontinuation rather than a temporary delay, this particular supply problem may be permanent for that maker. Importantly, the same 1 mg patch is still listed by several other companies that are not part of this shortage report, so the medicine itself remains on the market.
Here is how to handle it:
- Do not stop, skip, or change how you use your patch on your own.
- Ask your pharmacy to try sourcing the same 1 mg scopolamine patch from another maker (for example Mylan, Baxter's Transderm Scop, Rhodes, Amneal, or Zydus). It may not be in local stock, but they can check wholesalers.
- If your exact patch cannot be found, ask your prescriber or pharmacist about a suitable alternative.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually make these calls. Local stock may differ from this national data.
- Ask your pharmacy to check other companies’ versions, other strengths, package sizes, and nearby stores — the options below are a starting point.
- If this is part of an ongoing or essential regimen (for example HIV, seizure, heart, transplant, diabetes or mental-health medicines), arrange continued supply before you run out rather than rationing doses.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get scopolamine?
FDA shortages are company-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every company that lists scopolamine patches is necessarily short. Below are the other listings in the current FDA NDC Directory that are not reported in shortage: the same medicine from companies that haven’t reported a problem (the reporting company is excluded), and other dosage forms. Some listings are repackagers, which relabel another company’s product. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine from other companies (not reporting a shortage)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from companies that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Company | NDC |
|---|---|---|---|---|
| Scopolamine | SCOPOLAMINE 1 mg/3d | Patch · Transdermal | Mylan Pharmaceuticals Inc. | 00378-6470-44 |
| Transderm Scop | SCOPOLAMINE 1 mg/3d | Patch, Extended Release · Transdermal | Baxter Healthcare Corporation | 10019-0008-01 |
| Scopolamine | SCOPOLAMINE 1 mg/3d | Patch, Extended Release · Transdermal | Rhodes Pharmaceuticals LLC | 42858-0150-14 |
| Scopolamine | SCOPOLAMINE 1.5 mg/1 | Patch, Extended Release · Transdermal | Ingenus Pharmaceuticals, LLC | 50742-0505-04 |
| Scopolamine Trandermal System | SCOPOLAMINE 1 mg/1 | Patch, Extended Release · Transdermal | Bryant Ranch Prepack | 63629-8450-01 |
| Scopolamine | SCOPOLAMINE 1 mg/3d | Patch, Extended Release · Transdermal | Amneal Pharmaceuticals NY LLC | 69238-1662-02 |
| Scopolamine | SCOPOLAMINE 1 mg/3d | Patch, Extended Release · Transdermal | Zydus Pharmaceuticals USA Inc. | 70710-1846-02 |
| Scopolamine | SCOPOLAMINE 1 mg/3d | Patch, Extended Release · Transdermal | Bryant Ranch Prepack | 71335-3013-01 |
Other dosage forms of scopolamine
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 21 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Scopolamine 1 mg/3d | Mylan | 24 patches | $4.336 | AB | Availability likely |
| scopolamine 1 mg/3d | Actavis | 4 patches | $4.336 | AB | Availability likely |
| Scopolamine 1 mg/3d | Rhodes | 10 patches | $4.336 | AB | Availability likely |
| Scopolamine Transdermal System 1 mg | Padagis | 1 patch | $4.336 | AB | Availability likely |
| Scopolamine 1.5 mg | Ingenus | 1 patch | $4.336 | AB | Availability likely |
| Scopolamine 1 mg/3d | Amneal | 10 patches | $4.336 | AB | Availability likely |
| Scopolamine 1 mg/3d | Zydus | 10 patches | $4.336 | AB | Availability likely |
| Transderm Scop 1 mg/3d | Baxter | 1 patch | — | AB | FDA listed |
| Scopolamine 1 mg/3d | A-S | 4 pouches | — | AB | FDA listed |
| scopolamine 1 mg/3d | A-S | 1 d | — | AB | FDA listed |
| Scopolamine Trandermal System 1 mg | Bryant | 1 patch | — | AB | FDA listed |
| Scopolamine Trandermal System 1 mg | Bryant | 1 patch | — | AB | FDA listed |
| Scopolamine Trandermal System 1 mg | Bryant | 1 patch | — | AB | FDA listed |
| Scopolamine 1.5 mg | NuCare | 1 patch | — | AB | FDA listed |
| Scopolamine 1 mg/3d | Zydus | 10 patches | — | AB | FDA listed |
| Scopolamine Transdermal System 1 mg | Bryant | 1 patch | — | AB | FDA listed |
| Scopolamine 1 mg/3d | Bryant | 4 patches | — | AB | FDA listed |
| Scopolamine 1 mg/3d | Bryant | 10 patches | — | AB | FDA listed |
| Scopolamine 1 mg/3d | Bryant | 24 patches | — | AB | FDA listed |
| Scopolamine Trandermal System 1 mg | Bryant | 1 patch | — | AB | FDA listed |
| Scopolamine 1 mg/3d | Bryant | 4 patches | — | AB | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of scopolamine — that fall in the same broad treatment class (antiemetic/antivertigo agents) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Codes & classification for pharmacists and billers
Where does this data come from?
Scopolamine shortage FAQs
Is scopolamine still in shortage?
Which strengths of scopolamine are affected?
Which scopolamine products are affected?
When will scopolamine be available again?
Can I still get scopolamine somewhere?
What should I do if I take scopolamine?
Still have a question about the scopolamine shortage?
Ask a pharmacist about this shortage →View Scopolamine Transdermal System on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (companies listing the same ingredient & form — the "other companies" the rating counts); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.